ATLAS: Patient-Reported Outcomes From Phase III Study of Switch to Long-Acting Injectable Cabotegravir + Rilpivirine in Virologically Suppressed Patients

July 21-24, 2019; Mexico City, Mexico
97% of patients receiving long-acting injectable therapy said that they preferred it to continued daily oral ART.
Format: Microsoft PowerPoint (.ppt)
File Size: 223 KB
Released: July 25, 2019

Acknowledgements

Provided by USF

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
IAS 2019 Media Partner Logo
Educational grant provided by:
Gilead Sciences
ViiV Healthcare

Related Content

Dr Sylvia Ojoo discusses data on cryptococcal meningitis in people with HIV from the fall 2022 HIV conferences, from Clinical Care Options (CCO)

person default Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB Released: December 6, 2022

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Released: November 30, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings